GRPN gained 3.9% on the week to close at $17.26 — a second consecutive week of recovery — yet the most telling development isn't the price, it's a meaningful shift in the borrow market that deserves careful reading.
The clearest change this week is in availability. After spending the better part of six weeks with availability locked below 2% — and touching a floor of just 0.5% on June 5 — the lending pool has opened up noticeably. Availability jumped to 11.9% by June 16, a sixfold increase from the prior week's reading of around 1.9%. That remains tight by any normal measure, but it's a genuine loosening relative to the near-total lock that defined May and early June. To put the context in proportion: the 52-week low availability was 0.5%, and the pool spent weeks grinding along that floor. The move to 11.9% suggests fresh shares have entered the lending market — possibly connected to the CEO's large June 11 sale, which put 1.35 million shares into circulation. Cost to borrow has edged up alongside, rising 8.8% on the week to 1.83%, and up nearly 20% over the past month — modest in absolute terms but tracking in the wrong direction for anyone adding to short exposure. Short interest itself has barely moved: 31% of the free float, down just 2.2% on the week, continuing the glacial trimming trend noted in previous sessions. The shorts are not running. They are adjusting at the edges while holding the core position.
Options positioning offers a mildly contrasting read. Call activity dominates at a put/call ratio of 0.36, near the lowest level of the past year — its 52-week low is 0.3585. That's well below the 20-day average of 0.38 and about 1.2 standard deviations light on put demand. Options traders are not hedging aggressively into this setup. The combination — a tightly borrowed stock, a large short base, and a call-skewed options market — is the kind of configuration that can move sharply on any unexpected positive catalyst, though the direction of travel depends entirely on whether that catalyst appears.
The Street picture is split and somewhat stale, which itself tells a story. The most recent action of note came from Goldman Sachs in mid-May, when the firm raised its target from $10 to $13 while keeping a Sell rating — an acknowledgment that the stock has run, not a change of conviction. The mean price target across the analyst panel is $26.33, well above the current price, but that figure is pulled heavily by older bull-side targets from Northland Capital Markets and Roth Capital, both of which set targets in the $39–$47 range during 2025 when the stock was trading at different levels. The bear case centers on management's own guidance: billings down 2.5–5%, revenue down 5–7.5%, and adjusted EBITDA shrinking materially. The ORTEX short score, at 76.4, has crept higher for nine straight sessions — a signal that the data-driven short thesis is being reinforced, not challenged, by current positioning metrics.
The institutional register adds nuance. Pale Fire Capital, the Czech firm and largest holder at 26.8% of shares, has not moved its position. That structural anchor is unchanged. What has moved is the CEO: Dusan Senkypl sold 1.35 million shares on June 11 at $16.54, a $22.3 million disposal representing roughly 3.2% of the company. The 90-day net insider figure across all executives is a net sale of $23.7 million. The CFO and COO both trimmed in May. The direction is uniform — insiders have consistently reduced exposure into the stock's relative strength. That pattern has not changed this week.
Next up: the Q1 earnings print is scheduled for August 6. The last two results triggered one-day moves of 9% and 12% to the upside — the stock has a history of reacting violently to these releases. With 31% of the float short and availability now slightly less constrained than it was a week ago, how the borrow market evolves between now and that date will be the tension worth tracking.
See the live data behind this article on ORTEX.
Open GRPN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
